Adamas Pharmaceuticals Inc (ADMS) : Nexthera Capital Lp added new position in Adamas Pharmaceuticals Inc during the most recent quarter end. The investment management firm now holds 117,000 shares of Adamas Pharmaceuticals Inc which is valued at $1.7 Million , the company said in a statement filed on May 13, 2016 with the SEC.Adamas Pharmaceuticals Inc makes up approximately 1.87% of Nexthera Capital Lp’s portfolio.
Other Hedge Funds, Including , Dekabank Deutsche Girozentrale added ADMS to its portfolio by purchasing 10,800 company shares during the most recent quarter which is valued at $157,464. Diam Ltd. sold out all of its stake in ADMS during the most recent quarter. The investment firm sold 11,494 shares of ADMS which is valued $168,962. Princeton Alpha Management Lp added ADMS to its portfolio by purchasing 20,065 company shares during the most recent quarter which is valued at $294,956. Adamas Pharmaceuticals Inc makes up approx 0.05% of Princeton Alpha Management Lp’s portfolio. Russell Frank Co sold out all of its stake in ADMS during the most recent quarter. The investment firm sold 83,773 shares of ADMS which is valued $1.4 Million.Quantbot Technologies Lp reduced its stake in ADMS by selling 2,604 shares or 80.05% in the most recent quarter. The Hedge Fund company now holds 649 shares of ADMS which is valued at $10,955.
Adamas Pharmaceuticals Inc opened for trading at $16.3 and hit $16.45 on the upside on Wednesday, eventually ending the session at $16.27, with a gain of 0.74% or 0.12 points. The heightened volatility saw the trading volume jump to 1,47,515 shares. Company has a market cap of $352 M.
Many Wall Street Analysts have commented on Adamas Pharmaceuticals Inc. Shares were Reiterated by Mizuho on May 12, 2016 to “Neutral” and Lowered the Price Target to $ 16 from a previous price target of $17 .Company shares were Reiterated by Mizuho on Apr 28, 2016 to “Neutral”, Firm has raised the Price Target to $ 17 from a previous price target of $14 .Adamas Pharmaceuticals Inc was Initiated by JMP Securities to “Mkt Outperform” on Apr 1, 2016.
Adamas Pharmaceuticals Inc. is a specialty pharmaceutical company focused on development and commercialization of therapeutics targeting chronic disorders of central nervous systems (CNS). It is engaged in modifying pharmacokinetic (PK) profiles of approved drugs to create therapeutics for use alone and in fixed-dose combination products. It develops its lead product ADS-5102 (amantadine hydrochloride) for a complication associated with treatment of Parkinson’s disease known as levodopa induced dyskinesia and as a treatment for one or more additional CNS indications. Its other product candidate is ADS-8704. Through a partnership with Forest Laboratories Holdings Limited its portfolio includes two drugs commercially available in the United States: Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) and Namenda XR (memantine hydrochloride) extended release and donepezil hydrochloride) and Namenda XR (memantine hydrochloride) extended release capsules.